Allogene Therapeutics: Funding, Investors & Team (Oct 2026)
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Allogene Therapeutics has raised $200M across 1 funding round on record, the most recent an undisclosed round of $200M announced in Apr 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Allogene Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Allogene Therapeutics Funding Rounds
Allogene Therapeutics Founders and Leadership Team
Contact details for the Allogene Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Allogene Therapeutics Funding Compared to Other Biotechnology Startups
Allogene Therapeutics' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Allogene Therapeutics in Biotechnology and South San Francisco
Companies Similar to Allogene Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Allogene Therapeutics Funding FAQs
What does Allogene Therapeutics do?
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
How much funding has Allogene Therapeutics raised?
Allogene Therapeutics has raised $200M across 1 round on record. The most recent is an undisclosed round of $200M announced in Apr 2026.
When did Allogene Therapeutics last raise funding?
Allogene Therapeutics' most recent funding round on record is an undisclosed round of $200M, announced in Apr 2026.
Who founded Allogene Therapeutics?
FundedIQ lists David Chang (Founder) at Allogene Therapeutics.
Where is Allogene Therapeutics headquartered?
Allogene Therapeutics is based in South San Francisco, California, United States.
How many employees does Allogene Therapeutics have?
Allogene Therapeutics is in the 101-250 employee band.
How does Allogene Therapeutics' funding compare to other Biotechnology startups?
Allogene Therapeutics' latest round of $200M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Allogene Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Allogene Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.